Microsoft disclosed that Reid Hoffman will not stand for re-election to its board at the company's 2026 annual shareholder meeting, ending a board role that began in 2017 after Microsoft's acquisition of LinkedIn.

What the filing says

The June 5 Form 8-K says Hoffman informed Microsoft on June 2 that he would not seek another term. He will continue serving as a director until the annual meeting. Microsoft also stated that the decision was not the result of any disagreement with management over operations, policies, or practices.

That is the primary-source version of the board change. It does not name a new role or startup as the reason for the decision.

The AI angle

TechCrunch reported that Hoffman is stepping away to focus on his AI drug-discovery startup. Earlier TechCrunch and CNBC coverage identify that company as Manas AI, co-founded by Hoffman and oncologist Siddhartha Mukherjee. TechCrunch reported in January 2025 that Manas had raised $24.6 million, while CNBC described the company as focused on applying AI to drug discovery.

The move is notable because Hoffman has been one of Microsoft's more visible AI-era advisers, with ties across LinkedIn, OpenAI, Inflection, and venture investing. The conservative takeaway is not that Microsoft's AI strategy changes overnight. It is that a longtime Microsoft director is shifting more attention toward applied AI in biotech, a field where foundation-model techniques are increasingly being tested against slow, expensive research workflows.